ValuEngine upgraded shares of NewLink Genetics Corporation (NASDAQ:NLNK) from a sell rating to a hold rating in a research report report published on Friday, May 19th.
NLNK has been the subject of several other research reports. Jefferies Group LLC increased their price target on NewLink Genetics Corporation from $12.00 to $15.00 and gave the company a hold rating in a report on Wednesday, March 1st. Stifel Nicolaus increased their price target on NewLink Genetics Corporation from $22.00 to $26.00 and gave the company a buy rating in a report on Wednesday, March 1st. Zacks Investment Research cut NewLink Genetics Corporation from a buy rating to a hold rating in a report on Friday, March 3rd. SunTrust Banks, Inc. raised NewLink Genetics Corporation from a hold rating to a buy rating and increased their price target for the company from $12.00 to $30.00 in a report on Thursday, March 30th. Finally, Cantor Fitzgerald reiterated an overweight rating and issued a $32.00 price objective (up from $20.00) on shares of NewLink Genetics Corporation in a research report on Saturday, April 22nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of $21.00.
NewLink Genetics Corporation (NLNK) traded up 0.82% on Friday, reaching $6.12. The company’s stock had a trading volume of 569,380 shares. The stock has a 50-day moving average of $13.54 and a 200-day moving average of $14.68. NewLink Genetics Corporation has a one year low of $5.90 and a one year high of $25.17. The stock’s market cap is $178.86 million.
NewLink Genetics Corporation (NASDAQ:NLNK) last announced its earnings results on Thursday, May 4th. The biotechnology company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.10. NewLink Genetics Corporation had a negative return on equity of 61.98% and a negative net margin of 250.91%. The business had revenue of $2.76 million during the quarter, compared to analysts’ expectations of $2.68 million. On average, analysts predict that NewLink Genetics Corporation will post ($3.05) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2017/06/16/valuengine-upgrades-newlink-genetics-corp-nlnk-to-hold-updated-updated.html.
A number of large investors have recently made changes to their positions in NLNK. Tyers Asset Management LLC acquired a new stake in shares of NewLink Genetics Corporation during the fourth quarter worth $114,000. First Mercantile Trust Co. acquired a new stake in shares of NewLink Genetics Corporation during the first quarter worth $143,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of NewLink Genetics Corporation during the first quarter worth $145,000. Elkfork Partners LLC acquired a new stake in shares of NewLink Genetics Corporation during the fourth quarter worth $157,000. Finally, Baird Financial Group Inc. acquired a new stake in shares of NewLink Genetics Corporation during the fourth quarter worth $168,000. 51.91% of the stock is currently owned by institutional investors.
NewLink Genetics Corporation Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.